STOCK TITAN
  1. Home
  2. News
  3. JNJ

Johnson & Johnson - JNJ STOCK NEWS

Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.

Johnson & Johnson (NYSE: JNJ) is an American multinational corporation founded in 1886, widely recognized as the world’s largest and most diversified healthcare company. The company is structured into three main segments: pharmaceuticals, medical devices and diagnostics, and consumer health products. The pharmaceutical division, which contributes significantly to the company's revenue, focuses on therapeutic areas such as immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The medical devices segment specializes in orthopedics, surgical instruments, and vision care. The consumer health division, known for products in baby care, beauty, oral care, over-the-counter drugs, and women's health, is set to be divested in 2023 under the new name Kenvue.

In recent developments, Johnson & Johnson has made headlines with the expanded approval of CARVYKTI® (ciltacabtagene autoleucel), a one-time infusion therapy for multiple myeloma. This approval is based on the successful Phase 3 CARTITUDE-4 study, showing a significant reduction in disease progression or death by 59% compared to traditional therapies. Such advancements underscore Johnson & Johnson's dedication to innovative treatments, particularly in oncology.

Financially, Johnson & Johnson generates over half of its revenue from the United States, with the pharmaceuticals and medical devices divisions driving the majority of cash flows. The company continues to invest heavily in research and development, aiming to transform healthcare through smarter and less invasive treatments. Their strategic partnerships and focus on emerging markets further cement their position as a leader in the healthcare industry.

With a commitment to improving global health, Johnson & Johnson's innovative solutions span across the full spectrum of healthcare, striving to prevent, treat, and cure complex diseases. For more information, visit their official website at www.jnj.com.

News

Johnson & Johnson Reports Q4 and Full-Year 2023 Results

Rhea-AI Summary
Johnson & Johnson (NYSE: JNJ) reported a 7.3% sales growth to $21.4 billion in the fourth quarter of 2023, with operational growth of 7.2% and adjusted operational growth of 5.7%. Earnings per share (EPS) increased by 39.3% to $1.70, and adjusted EPS increased by 11.7% to $2.29. The full-year reported sales grew by 6.5% to $85.2 billion, with operational growth of 7.4% and adjusted operational growth of 5.9%. The EPS for the full year decreased by 15.3% due to a special one-time charge in the first quarter, but the adjusted EPS increased by 11.1%. The company re-confirmed guidance for 2024 with operational sales growth of 5.0% - 6.0% and adjusted operational EPS of $10.55 - $10.75. Johnson & Johnson's regional sales and segment sales results also showed positive growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
earnings
-
News

Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer

Rhea-AI Summary
Johnson & Johnson (JNJ) strengthens its commitment to oncology innovation by acquiring Ambrx Biopharma, Inc. (AMAM) in an all-cash merger transaction for approximately $2.0 billion. Ambrx's clinical and preclinical programs, including lead product candidate ARX517, a prostate-specific membrane antigen (PSMA)-targeting antibody drug conjugate (ADC), align with J&J's goal of developing next-generation ADCs and targeted oncologic therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
acquisition
-
News

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2024

Rhea-AI Summary
Johnson & Johnson (NYSE: JNJ) declares a cash dividend of $1.19 per share for the first quarter of 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
dividends earnings
News

Key Talc Lawyers: Planned “Prepack” J&J Bankruptcy is “Farce” and Improper Litigation Tactic

Rhea-AI Summary
Johnson & Johnson (JNJ) faces mounting legal challenges as recent meso settlements confirm culpability and financial obligation to thousands of women who developed cancer from talc exposure. Attorneys representing ovarian cancer victims warn that J&J's bankruptcy strategy will not succeed, with upcoming jury trials in 2024 and recent limited settlements confirming the presence of cancer-causing asbestos in talc products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
none
-
News

Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results

Rhea-AI Summary
Johnson & Johnson (NYSE: JNJ) will host a conference call on January 23rd to review fourth-quarter results. Joaquin Duato, Chairman and CEO, Joseph J. Wolk, Executive Vice President and Chief Financial Officer, and Jessica Moore, Vice President, Investor Relations will host the call. The webcast and presentation material will be accessible at Johnson & Johnson’s website. A replay of the webcast will be available. Telephone dial-in numbers are provided for both U.S. and international participants. The press release will be available the morning of the conference call. Please note the first-quarter date of Tuesday, April 16th, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.01%
Tags
conferences earnings
-
News

Johnson & Johnson to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Johnson & Johnson (NYSE: JNJ) to participate in the 42nd Annual J.P. Morgan Healthcare Conference. Joaquin Duato, Chairman and CEO, to represent the company in a session on January 8th, 12:45 p.m. (Eastern Time). Audio webcast available on www.investor.jnj.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
conferences
News

Publication in Bloomberg Law: ‘A Third J&J Bankruptcy Attempt Won’t Resolve Victims’ Talc Claims’ by Andy Birchfield

Rhea-AI Summary
Company XYZ (XYZ) Announces Strategic Partnership with ABC Corp - Press Release Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
-
News

Johnson & Johnson Announces Key Drivers for Long-Term Competitive Growth at Enterprise Business Review

Rhea-AI Summary
Johnson & Johnson (NYSE: JNJ) presents long-term operational sales outlook, expecting 5-7% CAGR for 2025-2030 in both Enterprise and Innovative Medicine, with potential peak year sales assets of $5B+ and $1-5B. MedTech anticipates upper-range market growth of 5-7% through 2027. Company guides 2024 operational sales growth of 5-6% and adjusted operational EPS of $10.55-$10.75, reflecting 7.3% growth at the midpoint.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
-
News

Johnson & Johnson Names Eugene A. Woods, Chief Executive Officer of Advocate Health, to its Board of Directors

Rhea-AI Summary
Johnson & Johnson (JNJ) appoints Eugene A. Woods, CEO of Advocate Health, to its Board of Directors. Woods brings extensive experience in leading and transforming healthcare systems, prioritizing high-quality patient care, and advocating for equitable healthcare.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
management
News

Johnson & Johnson MedTech Acquires Laminar, Inc.

Rhea-AI Summary
Johnson & Johnson MedTech (JNJ) acquires Laminar, Inc., a medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib). The acquisition was completed for an upfront payment of $400 million, with additional potential clinical and regulatory milestone payments in 2024 and beyond. Laminar's innovative approach uses rotational motion to eliminate the LAA, different from current commercial catheter-based procedure devices. Laminar recently received FDA approval for the U.S. pivotal study, which will begin enrollment in early 2024. The acquisition will require an in-process research and development charge, reducing operational and reported Adjusted EPS by approximately $0.17 from guidance previously issued for fiscal year 2023. The new expected operational and reported Adjusted EPS ranges for 2023 are now $9.85 to $9.91 and $9.90 to $9.96, respectively. Additionally, the asset acquisition is expected to have an approximate negative $0.15 EPS impact in fiscal year 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
acquisition

FAQ

What is the current stock price of Johnson & Johnson (JNJ)?

The current stock price of Johnson & Johnson (JNJ) is $162.3 as of February 21, 2025.

What is the market cap of Johnson & Johnson (JNJ)?

The market cap of Johnson & Johnson (JNJ) is approximately 344.6B.

What are the main business segments of Johnson & Johnson?

Johnson & Johnson operates through three main segments: pharmaceuticals, medical devices and diagnostics, and consumer health products.

What recent developments have there been in Johnson & Johnson's pharmaceutical division?

Recently, Johnson & Johnson received expanded FDA approval for CARVYKTI®, a therapy for multiple myeloma, based on positive Phase 3 study results.

What products are included in Johnson & Johnson’s consumer health segment?

The consumer health segment includes products in baby care, beauty, oral care, over-the-counter drugs, and women's health.

What is CARVYKTI®?

CARVYKTI® is a one-time infusion therapy for multiple myeloma, recently approved for expanded use due to its efficacy in delaying disease progression.

What percentage of Johnson & Johnson's revenue is generated in the United States?

Over half of Johnson & Johnson’s total revenue is generated in the United States.

What is the focus of Johnson & Johnson’s medical devices segment?

The medical devices segment focuses on orthopedics, surgical instruments, and vision care.

What changes are happening with Johnson & Johnson’s consumer health division?

The consumer health division is being divested in 2023 and will operate under the new name Kenvue.

How does Johnson & Johnson contribute to global healthcare?

Johnson & Johnson develops innovative solutions to prevent, treat, and cure complex diseases, aiming to improve global health.

Where can I find more information about Johnson & Johnson?

More information about Johnson & Johnson can be found on their official website at www.jnj.com.

What therapeutic areas does Johnson & Johnson's pharmaceutical division focus on?

The pharmaceutical division focuses on immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases.
Stock JNJ logo
Johnson & Johnson

NYSE:JNJ

JNJ Rankings

#rank Ranked by Market Cap
#rank Ranked by Dividends

JNJ Stock Data

344.63B
2.40B
0.06%
73.25%
0.68%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
NEW BRUNSWICK